Overview
International law firm McDermott Will & Emery represented Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company, in connection with its $110 million private placement with potential aggregate financing up to $275 million if all warrants are exercised.
Inhibikase develops Abelson Tyrosine Kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative diseases like Pulmonary Arterial Hypertension (PAH) and Parkinson’s. The company intends to use the net proceeds from the private placement to finance the execution of their Phase 2b ‘702’ trial in PAH and for general corporate purposes.
The McDermott team was led by Merrill Kraines, Todd Kornfeld, Brandon Sloane, Brian Tratner, and Caroline Samuelson.
Read Inhibikase’s closing announcement here.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
